Clinicians frequently face the decision of whether to continue aspirin when starting patients on warfarin. We performed a meta-analysis to characterize the tradeoffs involved in this common clinical dilemma.
taking daily aspirin is approaching 23 million. 4 At the same time, clinicians are being encouraged to use warfarin more frequently in response to growing evidence of benefit in multiple conditions. [5] [6] [7] [8] [9] [10] [11] As a consequence, warfarin is increasingly recommended in patients who are already on aspirin, raising the question of whether or not to continue the aspirin once anticoagulation is initiated. Reasonable clinical arguments have been made for both approaches. On the one hand, proponents of continuing aspirin with warfarin therapy have hypothesized additive antithrombotic protection when both platelet function and coagulation factor activity are suppressed. On the other hand, those warning against dual therapy have cautioned that the potential for increased bleeding would be unacceptably high, surely outweighing any theoretical benefits.
In order to describe these tradeoffs quantitatively, we performed a systematic review and meta-analysis of any randomized trials comparing adjusted-dose warfarin plus aspirin versus adjusted-dose warfarin alone. We aimed to characterize the efficacy and safety of the two treatment strategies by comparing thromboembolic, bleeding, and mortality outcomes in conditions in which these drugs might be used concomitantly.
METHODS

Data Sources
We used a Cochrane Optimized Medline Search Strategy (see Appendix) to locate randomized, controlled trials involving warfarin (or comparable oral vitamin K antagonists) and aspirin published in English language journals between 1966 and October 2003. Other large databases includingJGIM (DARE) were searched using the same strategy. We manually reviewed the bibliographies of selected and related articles for any pertinent references overlooked by the computerized searches and explored national and international conference proceedings for abstracts of relevant work not yet published.
Study Selection
References identified by the computerized searches were imported into a computer database for review. Full text articles were obtained of references that either appeared to meet the inclusion criteria or could not be excluded by abstract and title review alone. Studies were ultimately selected for the synthesis if they 1) described an explicitly randomized trial that compared adjusted-dose warfarin plus aspirin versus adjusted-dose warfarin alone; 2) targeted all anticoagulation to an international normalized ratio (INR) goal ≥2 (two trials predating the INR system 12, 13 were judged to reflect comparable anticoagulation goals); 3) reported event rates for at least one of the outcomes of interest (thromboembolism, hemorrhage, and all-cause mortality); and 4) had a minimum of 3 months of follow-up. Blinding of treatment and outcome assessments was tracked but not utilized as an inclusion/exclusion criterion. Reviewers were not blinded to journal titles, author names, or institutional affiliations.
Data Extraction
For each study selected for the synthesis two reviewers independently extracted the data of interest. Items recorded for each trial included authors' names, year of publication, period of trial conduction, patient characteristics, study design, number enrolled, treatment arms included, target INRs, mean INRs achieved, aspirin dosages, rates of reported outcomes, and duration of follow-up. If important pieces of data could not be located in a published report, efforts were made to contact the corresponding authors in order to obtain the missing details. Information was entered into a data collection spreadsheet by each reviewer and then compared for consistency. Disagreements were resolved via discussion.
Data Synthesis
Statistical calculations were performed using Revman software.
14 For each trial, the relative risk and 95% confidence interval of warfarin plus aspirin versus warfarin alone were calculated for each endpoint of interest. For warfarin indications with more than one trial assessing comparable treatment regimens, the χ 2 test for heterogeneity was used to assess the appropriateness of pooling the individual study results. If a grouping of trial results was found to be heterogeneous (using a P value cutoff of .10), the χ 2 test of heterogeneity was recalculated excluding each member trial in sequence to determine the largest grouping of homogeneous trials. Where appropriate, final pooled risk estimates by warfarin indication were calculated using a random effects model with a P value <.05 being considered significant. Absolute risk reductions for each endpoint by warfarin indication were manually calculated by subtracting the pooled event rates for each treatment group from the pooled event rates for each corresponding control group.
RESULTS
Study Selection
Eight hundred twenty-five potential articles were initially located by the computerized searches. As shown in Figure 1 , the majority of exclusions were made due to lack of randomization or missing treatment arms. Manual reference review led to the identification of one additional randomized trial. 13 Ultimately, the searches resulted in a collection of nine qualifying trials, 12,13,15 -22 which together addressed three warfarin indications (Table 1) . 
Study Characteristics
A summary of the trials included in the synthesis is shown in Table 2 . Five involved mechanical heart valve recipients, 12,13,15 -18 three were performed in post-myocardial infarction (post-MI) subjects, [19] [20] [21] and one had been conducted in atrial fibrillation patients at high risk for thromboembolic disease. 22 For each warfarin indication, the trials were further stratified to separate those that evaluated a single warfarin regimen with and without aspirin (single intervention) 12,13,15 -17,19,22 from those that compared moderateintensity warfarin plus aspirin versus higher-intensity warfarin alone (double intervention). 18, 20, 21 This division permitted assessment of the trials that specifically isolated the effect of aspirin separately from those that varied both the presence of aspirin and the intensity of the anticoagulation.
Mechanical Heart Valves
Thromboembolic Events. Thromboembolic events were defined similarly in all five valve trials and typically included valve thromboses, systemic emboli, cerebrovascular emboli, and MIs occurring in the absence of significant coronary artery lesions. Transient ischemic attacks were included in four of the five trials. 12, 13, 15, 18 As shown in Table 3 , thromboembolic event rates were lower in the combination therapy groups in all four of the single-intervention trials 18 thromboembolic event rates were low in both groups and essentially equivalent.
Major Bleeding. Major bleeding typically included episodes that led to a drop in hemoglobin of >2 g/dL, required hospitalization or transfusion of blood products, or resulted in death. Again shown in Table 3 , major bleeding events were increased or equivalent with warfarin plus aspirin in all three of the single-intervention trials reporting this outcome 13, 15, 16 (pooled RR, 1.58; 95% CI, 1.02 to 2.44; ARR, −5%; NNH, 20). Conversely, the double-intervention trial 18 found fewer bleeding events in the combination therapy group.
All-cause Mortality. Because the test of heterogeneity was significant for the combined group (P = .07), we pooled the single-intervention all-cause mortality findings both before and after excluding the Laffort results (the only trial finding increased mortality with combination therapy). 15 Using the data from all four trials 12 Table 5 ). The wide confidence intervals however, caution against drawing any major conclusions from the results.
DISCUSSION
Despite the growing prevalence of aspirin use among patients starting warfarin, five of the nine randomized trials that specifically assessed the benefits and harms of combination warfarin plus aspirin therapy were restricted to patients with mechanical heart valves. Three involved an indication rarely used in the United States (routine post-MI) and only one focused on patients with the most common chronic indication, atrial fibrillation. None included patients with any of the other ACCP Committee on Antithrombotic Therapy-sanctioned indications (Table 1) . 23 Nonetheless, some inferences can be drawn from the limited data available. Mechanical heart valve patients have a clear overall benefit from combining aspirin with warfarin therapy. Post-MI patients probably have a reduced risk of thromboembolic events but appear to have no decrease (and perhaps an increase) in overall mortality.
Finally, because the atrial fibrillation trial was terminated early, there are no data from which to draw conclusions regarding this increasingly prevalent indication. While a number of trials, reviews, and meta-analyses have evaluated varying combinations of warfarin and aspirin, 24-34 few have addressed the specific clinical question-"Should aspirin be continued in patients started on warfarin?" Instead, previous work has tended to focus on two other aspects of antithrombotic therapy, "What is the benefit of adding warfarin to aspirin?" (i.e., warfarin plus aspirin versus aspirin alone) and, "Can the intensity of warfarin be reduced if combined with aspirin?" (i.e., fixeddose/low-intensity warfarin (INR <2) plus aspirin versus 35 in its effort to be comprehensive the synthesis mixed trials addressing all three questions. Conversely, when previous investigators have focused specifically on questions comparable to our own, 36-39 their reviews have been confined to mechanical heart valve trials. To our knowledge, our report is the first to focus on the tradeoffs of concomitant aspirin use in multiple adjusted-dose warfarin indications. Nonetheless, our study is clearly limited by the small number of trials that fulfilled the inclusion criteria and the narrow scope of warfarin indications covered by the few qualifying trials. We did not have access to Excerpta Medica database but have no reason to believe that it contains additional relevant trials not detected by our present search strategy. While the initial study screening was performed by a single reviewer, our well-defined inclusion criteria made study selection straightforward and articles that presented any question were reviewed by both investigators prior to exclusion. Certainly the requirement that all warfarin be dose adjusted to INRs ≥2.0 eliminated many high-quality studies from the synthesis. Even so, because these same studies have shown INRs <2.0 to be inferior, thereby directing the current recommendations targeting INRs ≥2.0 for every standard warfarin indication, 23 the inclusion criterion was necessary in order to target the clinically relevant question. Additional limitations might stem from the poor availability of information to assess study quality, and the variation in treatment regimens used in the studies. Although we stratified the trials by "single" and "double" intervention status in order to assess the effects of the differing study designs separately, even among the single-intervention trials the target INRs ranged from as low as 2.0 to 2.5 to as high as 3.0 to 4.5. Similarly, the aspirin doses ranged from 75 to 1,000 mg per day. Despite the diversity, however, no obvious relationship between the study outcomes and the INR ranges or aspirin doses was detected. In fact, the highest bleeding rates were seen in a trial using both a conservative target INR range and a modest aspirin dose. 15 Admittedly, the primary aim of most trials evaluating warfarin and aspirin combinations has been to assess whether the addition of aspirin provides added protection in terms of the thrombosis risk for which the warfarin is indicated, without leading to excessive bleeding. While this question is different from asking whether it is safe to continue prophylactic aspirin (for prevention of MI and stroke) in patients requiring warfarin for alternative diagnoses (i.e., deep venous thrombosis, pulmonary embolism, stroke prevention in atrial fibrillation or following valve replacement, etc.), trials designed to address these questions would be virtually indistinguishable. Though the inclusion criteria might require that subjects also meet defined criteria for prophylactic aspirin (i.e., prior heart attack or >10% 10-year risk of cardiovascular disease), such trials would compare wafarin plus aspirin to warfarin alone and the outcomes of interest would include thromboembolic events, bleeding, and all-cause mortality.
Because our review was specifically intended to address aspirin use in patients requiring warfarin, we considered carefully whether the post-MI trials were appropriate for the synthesis. Indeed in the United States, aspirin has been the traditional first-line prevention therapy following acute MI, whereas warfarin has been reserved for patients intolerant to aspirin, with left ventricular mural thrombus or high-risk anterior wall motion abnormalities, or with recurrent thrombotic events on aspirin alone. With the publication of the most recent post-MI trial, 20 however, it appears that our question may be relevant for this patient group as well. Because both the warfarin plus aspirin and warfarinonly groups had fewer thromboembolic events compared to the aspirin-only group, attention is now being given to whether anticoagulation-based secondary prevention therapies should be more aggressively considered in this country. For those clinicians and patients who choose to focus on minimizing thromboembolic risk, these results suggest that combined warfarin plus aspirin therapy offers the best protection. On the other hand, for those who choose to focus on the broader overall mortality outcomes, the findings suggest that neither the addition of nor substitution with warfarin offers a mortality advantage over aspirin alone.
In the end, we are left with a striking lack of evidence regarding aspirin use in the most common warfarin indications. Unfortunately, the variations in outcomes among the conditions we were able to evaluate suggest that extrapolating from one warfarin indication to another may not be appropriate. Nonetheless, with over 2 million people in the United States affected by atrial fibrillation and approaching 200,000 new cases per year, 40 the issues raised here will only become more relevant. For now, decisions about the use of aspirin in most patients receiving warfarin will need to be individualized in the absence of adequate data.
